Previous passive antibody transfer experiments have indicated that immunity to a 46-kilodalton membrane glycoprotein (M-2) of Leishmania amazonensis may protect against infection with this parasite. In the studies described in this paper, we investigated the ability of the purified M-2 molecule to elicit a protective immune response in conjunction with Freund incomplete and complete adjuvants, saponin, and Corynebacterium parvum. Both relatively susceptible (BALB/c and CBA) and resistant (C57BL/6) strains of mice were examined. C. parvum appeared to be the most effective adjuvant in the three mouse strains tested. The level of protection varied with the mouse strain, although all animals received identical preparations of antigen and adjuvant. Immunization of CBA mice with the M-2 glycoprotein and C. parvum resulted in complete protection against a challenge infection of 104 and 106 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (104 L. amazonensis organisms). The level of protection observed is reflected by increased antibody response (immunoglobulins Gl and G2) developed to the M-2 molecule. The relationship of pure T-cell (nonantibody) immunity to this protection remains to be elucidated.
Leishmaniasis is a zoonotic parasitic disease caused by members of the protozoan genus Leishmania. The leishmanias are associated with a broad spectrum of disease (5) , ranging from simple cutaneous to visceral leishmaniasis. Estimates of the incidence of leishmaniasis vary (49) but suggest that annually several million new cases occur world wide.
The Leishmania parasite has a relatively simple life cycle (5) . The flagellated promastigotes multiply within the alimentary tract of the sandfly vector and subsequently migrate anteriorly. The promastigotes are then transmitted by the bite of the sandfly to a mammalian host, where they enter macrophages and transform into aflagellated amastigotes within the phagolysosomal vacuole.
Species of the Leishmania mexicana complex have a wide geographic distribution, including South and Central America, the West Indies and (to a limited extent) the southern United States (7, 11, 23, 25) . Members of the L. mexicana complex are associated with both simple and diffuse forms of cutaneous leishmaniasis. Diffuse cutaneous leishmaniasis, caused primarily by L. amazonensis and L. pifanoi in a fraction of infected individuals (30) , is characterized by disseminated large histiocytomalike nodules containing abundant parasites and by deficient cell-mediated immunity (7, 43) that may be associated with immunological suppression (35) . In general, these cases are resistant to chemotherapy (7) .
Vaccination, at least for the cutaneous forms of leishmaniasis, is possible. For centuries, vaccination with living organisms that produce a lesion has been practiced by the inhabitants of the Middle East. Such vaccination by infection generally is followed by lifelong immunity and has been the basis for vaccination programs in both Israel and the USSR (10) . Complications that occur with the live vaccine (10) indicate the need for an attenuated or defined vaccine * Corresponding author. for cutaneous leishmaniasis. Recent studies in animal model systems (18, 26, 33, 40) and humans (1, 24, 27 ) with irradiated or killed Leishmania organisms suggest that a nonlive vaccine is possible. In addition, recent studies of purified leishmanial antigenic components have resulted in significant (14, 37 ) protection in murine model systems.
Our laboratory has been involved in the identification of potentially protective Leishmania antigens by using monoclonal antibodies specific for membrane components (28, 30) . With L. amazonensis, monoclonal antibodies specific for a 46-kilodalton (kDa) (9, 25, 37) membrane glycoprotein (M-2) specific for the promastigote stage of the parasite (2, 20; P. J. Langer and D. McMahon-Pratt, unpublished data) completely protects in passive antibody transfer experiments against an infective challenge of 103 or 104 promastigotes. The protection observed in the passive-immunity experiments did not appear to be dependent on complement (2) . In the studies described here, the effectiveness of the M-2 glycoprotein in eliciting protection was evaluated in direct-immunization studies. The data presented suggest that, with T-cell help, a mature immune response to this antigen is generated which results in protection. (16, 17, 46) and most likely reflect an error in counting the clumped amastigotes. The plates were scored at day 10, since preliminary experiments showed that this was the optimal time required to detect growth of the cloned amastigotes.
MATERIALS AND METHODS

Mice
Indirect radioimmunoassay. Parasite membranes were sonicated and incubated overnight at 4°C on U-bottom polyvinyl chloride microtiter plates (Falcon 3911). The microtiter plates were washed with PBS containing 5% fetal bovine serum and 0.02% NaN3. Mouse sera were serially diluted in PBS and incubated with the antigen-coated plates. The plates were washed with PBS-fetal bovine serum, and affinity purified '25I-labeled rabbit F(ab')2 anti-mouse immunoglobulin (5 to 10 ng per well; 105 cpm) was added to the wells and incubated for 1 h at 0°C. Microtiter plates were washed and air dried, and the amount of bound radioactivity per well was determined with an AutoGamma counter (Packard Instrument Co., Inc., Rockville, Md.) as previously described (19, 30 In the next set of protective immunization studies, experiment 1, the adjuvant used in conjunction with the M-2 glycoprotein was varied in an attempt to maximize the level of protection afforded by the M-2 glycoprotein in BALB/c mice. Saponin and C. parvum were chosen and tested against incomplete Freund adjuvant to determine which elicited an optimal immune response. These adjuvants have been successfully used in vaccine studies in conjunction with antigens in other protozoan parasite systems (28, 33, 34, 42 (Fig. 1) were tested for long-term immunity; all eventually succumbed to disease, except the C. parvum-M-2 glycoprotein group, in which 28% (3 of 11) of the mice infected with 103 L. amazonensis remained disease free for 9 months postchallenge.
Immunization of susceptible and resistant mouse strains. In experiment 2, C. parvum and saponin were used as adju- However, the course of infection appears to differ from that observed in BALB/c mice in that in the initial phase of infection the parasite burden (based on limitingdilution analysis) appeared to be contained for a period of time (months), dependent on the inoculating dose; subsequently, the nodules began to grow in an apparently unrestrained manner, similar to that observed in BALB/c mice.
In addition, the threshold inoculation dose for infection was about 10-fold higher for CBA mice than for BALB/c mice when L. amazonensis LTBOO16 was used. C57BL/6 mice maintained a chronic but contained infection for up to 6 months postinoculation with either 104 or 106 LTBOO16 strain promastigotes.
On the basis of lesion size, immunization with C. parvum and the M-2 glycoprotein showed the best protection from disease in the three strains of mice studied (Fig. 2) fection. The rest of the mice in these groups developed lesions smaller than those of the mice in the control groups; the visible onset of disease in the protected group was delayed from that observed in the control groups. Interestingly, intravenous immunization with the M-2 glycoprotein and saponin gave no apparent protection on the basis of lesion measurements.
Protection of BALB/c mice against infection was also (Fig. 2C and D) . Determinations were done in duplicate, as previously described (44) , by using two mice from each group. b Intraveneous immunization.
quantitated as a function of parasite burden by using a limited-dilution assay (46) . The results of these experiments ( (104), partial protection was observed in the group that had received M-2 and C. parvum but not in those that had received M-2 and saponin (Fig. 2) . Fifty percent of the animals (3 of 6) that received the lower inoculating dose were completely protected, showing no lesion development through the 6 months of observation postinfection.
Immunization of BALB/c mice subcutaneously with saponin and M-2. Since Howard and co-workers have described variation in protective immunity with the routes of vaccination (18, 26) and since the results with saponin and M-2 in experiment 1 (subcutaneous immunization) differed from the response of the immunized animals to the M-2 glycoprotein was assessed by Western blot analysis with membrane preparations of L. amazonensis as the antigen. Since M-2 is a glycoconjugate with one N-linked carbohydrate side chain of 2 kDa (32; unpublished data), it was possible that the protection observed was a result of additional cross-reaction with other carbohydrate-containing components. In addition, preparations of M-2 made subsequent to this study showed a minor (-1%) contaminant at 65 kDa, visible only on silver-stained sodium dodecyl sulfate-polyacrylamide gels. The immunized mice appeared to recognize primarily a 46-kDa (M-2) component (Fig. 4) . On longer exposures, weaker bands were apparent at higher molecular masses, as well as with components of 30 and 24 kDa, consistent with the proteolytic breakdown products of the M-2 molecule (20) observed to occur at a low level during membrane preparation. promastigotes. The M-2 glycoprotein is molecularly distinct from (i) the lipid-containing glycoconjugate of L. major (13, 14) that has been demonstrated to confer protection and (ii) GP-10/20, the glycoconjugates of L. amazonensis (36) (14) which is present on both developmental stages of the parasite. Consequently, other factors (adjuvant, mouse strain) may also determine the extent of protection.
Experiments with C. parvum, saponin, and incomplete Freund adjuvant as adjuvants consistently indicated that C. parvum was the most effective adjuvant in eliciting a protective immune response. Saponin has been used successfully as an adjuvant in protective immunity studies of other parasitic protozoa (28, 29, 42) in which, in certain cases, C. parvum was ineffective; however, saponin was not as effective an adjuvant as C. parvum in these studies. C. parvum has been shown to be an effective adjuvant in eliciting a protective response against infection with L. major when used together with whole parasites or a purified lipid-containing glycoconjugate (14, 33) . In addition, a recent study has shown that simultaneous injection of C. parvum with an infective inoculum of L. major led to modulation of disease (15) ; treatment with Mycobacterium bovis BCG has given similar effects in human patients (6) . C. parvum has been reported to enhance the T helper cell-antibody response to erythrocytes (IgG2>>IgM>IgGl) (48) . Enhancement of the antibody response was observed in this study; a significant effect was observed in the IgGl subclass, with the levels of antibody as follows: IgGl>IgG2>>IgM>>>IgG3. C. parvum has also been reported to enhance the level of natural killer (NK) and macrophage cell activity. NK cell activity has been indicated to affect the course of leishmanial infection (21) . Since the NK activity stimulated by C. parvum may last for several weeks (45) , NK cell activity may be involved in or facilitate the protective response observed here. Further work is required to determine this. The macrophage activation by C. parvum appears, however, to be VOL. 56, 1988 on November 6, 2017 by guest http://iai.asm.org/ Downloaded from short-lived (a period of days) (44) , and C. parvum-elicited macrophages have been reported to be tumoricidal but not leishmanicidal (12) . In addition, no apparent nonspecific adjuvant effects were observed in the control groups of mice that received C. parvum alone. Therefore, the action of C. parvum on macrophages in this study most likely results in the enhanced immune response to M-2 observed (T-cell-B-cell activation) rather than a direct leishmanicidal macrophage effect. With C. parvum, the level of protection observed in the three groups of mice studied varied from apparently complete protection, as observed in the susceptible CBA strain, to protection at only the 104 challenge infecting dose, as observed in the relatively resistant C57BL/ 6 strain. In the susceptible BALB/c strain and the C57BL/6 strain (104 inoculum), some of the animals (3 of 6 or 50%) immunized with C. parvum together with M-2 were completely protected while the rest were partially protected, showing a delay in onset of the disease. The reason for the differences observed in level of protection elicited in the three strains of mice are unclear, although the best protection obviously occurred in the strains of mice most susceptible to infection with L. amazonenesis. Differences have also been observed in the immune responses of these mouse strains to infection with L. amazonensis. Immunocytochemical studies of leishmanial lesion development suggest that, in contrast to C57BL/6 mice, there is in BALB/c mice a defect in T-cell (both L3T4+ and Lyt-2+) influx into the infected area (29) . Moreover, lymphokine-activated C57BL/ 6 macrophages have been shown to fail to destroy L. amazonensis (41) . Since these two mouse strains apparently differ in their immunological responses to the infecting leishmanial parasite, the immune effector mechanisms that must be activated by immunization to elicit a protective response may differ as well.
In addition, there is a difference in the immune response levels observed in the three mouse strains, as indicated by the levels of antibodies specific for the M-2 glycoprotein. The overall response level was greater in BALB/c and CBA mice than in C57BL/6 mice. Within the immunized groups of CBA and BALB/c mice, the level of protection correlated with the level of the antibody to M-2. The role of the antibody itself in protection against leishmaniasis is controversial. In transfer experiments, T cells but not the antibody from BALB/c mice protectively immunized with irradiated promastigotes of L. major gave significant protection, although antibody levels of the immunized donor mice showed a correlation with protection. Consequently, although the antibody level was indicative of the immune status of the animals, it did not appear to directly affect the protection observed (18, 26) . However, studies of ,u-suppressed mice (38, 39) suggest a role for B-cell-modulated effector T cells. Moreover, passive transfer of monoclonal antibodies to specific leishmanial components (2, 8, 14) can protect against an infective challenge. The role of antibodies in the protection observed in this study is unclear. Antibody levels may parallel the activation of specific effector mechanisms required for a protective response. The roles of T cells (subsets), B cells, and immune effector mechanisms (lymphokines) involved in the protection induced by the M-2 molecule are currently under investigation.
Previous studies with animal model systems and humans (1, 24) indicate that cross-protection occurs between Leishmania species that cause the cutaneous form of the disease. Recent experiments with heteroserum to the M-2 molecule (McMahon-Pratt, unpublished data), as well as recent Southern blot analyses (32) with the cloned M-2 gene suggest that the M-2 protein is not restricted to L. amazonensis, although the epitopes recognized by various monoclonal antibodies are species specific. Work is in progress to verify this. If the M-2 molecule or a member of a related family is present on various Leishmania species, the effect of M-2 in eliciting a protective immune response against other Leishmania species would be of interest. Recent efforts to develop a vaccine for leishmaniasis have focused on delineating defined antigenic components that produce an effective protective response, either alone or in combination with other defined antigenic molecules. This study suggests that the M-2 glycoprotein would be useful for the production of a defined vaccine against leishmaniasis.
